These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25218668)

  • 21. Insulin/IGF-1 Signaling Is Downregulated in Barrett's Esophagus Patients Undergoing a Moderate Calorie and Protein Restriction Program: A Randomized 2-Year Trial.
    Arcidiacono D; Zaramella A; Fabris F; Sánchez-Rodríguez R; Nucci D; Fassan M; Nardi M; Benna C; Cristofori C; Morbin T; Pucciarelli S; Fantin A; Realdon S
    Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Hur C; Nishioka NS; Gazelle GS
    J Natl Cancer Inst; 2004 Feb; 96(4):316-25. PubMed ID: 14970280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus.
    Yachimski P; Wani S; Givens T; Howard E; Higginbotham T; Price A; Berman K; Hosford L; Katcher PM; Ozanne E; Perzan K; Hur C
    Clin Gastroenterol Hepatol; 2015 Jan; 13(1):84-90. PubMed ID: 24681073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acetic acid chromoendoscopy in Barrett's esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video).
    Tholoor S; Bhattacharyya R; Tsagkournis O; Longcroft-Wheaton G; Bhandari P
    Gastrointest Endosc; 2014 Sep; 80(3):417-24. PubMed ID: 24713305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study.
    Buttar NS; Wang KK; Anderson MA; Dierkhising RA; Pacifico RJ; Krishnadath KK; Lutzke LS
    J Natl Cancer Inst; 2002 Mar; 94(6):422-9. PubMed ID: 11904314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
    Kaur BS; Khamnehei N; Iravani M; Namburu SS; Lin O; Triadafilopoulos G
    Gastroenterology; 2002 Jul; 123(1):60-7. PubMed ID: 12105834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
    de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
    Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett's esophagus: clue for the chemoprevention of esophageal carcinoma by antioxidants.
    Lee JS; Oh TY; Ahn BO; Cho H; Kim WB; Kim YB; Surh YJ; Kim HJ; Hahm KB
    Mutat Res; 2001 Sep; 480-481():189-200. PubMed ID: 11506813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis.
    Arcidiacono D; Antonello A; Fassan M; Nucci D; Morbin T; Agostini M; Nitti D; Rugge M; Alberti A; Battaglia G; Realdon S
    Dig Liver Dis; 2017 Jun; 49(6):630-638. PubMed ID: 28185837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
    Zhang Q; Yu C; Peng S; Xu H; Wright E; Zhang X; Huo X; Cheng E; Pham TH; Asanuma K; Hatanpaa KJ; Rezai D; Wang DH; Sarode V; Melton S; Genta RM; Spechler SJ; Souza RF
    Gastroenterology; 2014 Feb; 146(2):461-72.e6. PubMed ID: 24120473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
    Zhang T; Wang Q; Ma WY; Wang K; Chang X; Johnson ML; Bai R; Bode AM; Foster NR; Falk GW; Limburg PJ; Iyer PG; Dong Z
    EBioMedicine; 2019 Nov; 49():145-156. PubMed ID: 31707149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Barrett's metaplasia the source of adenocarcinomas of the cardia?
    Clark GW; Smyrk TC; Burdiles P; Hoeft SF; Peters JH; Kiyabu M; Hinder RA; Bremner CG; DeMeester TR
    Arch Surg; 1994 Jun; 129(6):609-14. PubMed ID: 8204035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
    Kitson SJ; Maskell Z; Sivalingam VN; Allen JL; Ali S; Burns S; Gilmour K; Latheef R; Slade RJ; Pemberton PW; Shaw J; Ryder WD; Kitchener HC; Crosbie EJ
    Clin Cancer Res; 2019 Apr; 25(8):2424-2432. PubMed ID: 30563932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia.
    Pouw RE; Wirths K; Eisendrath P; Sondermeijer CM; Ten Kate FJ; Fockens P; Devière J; Neuhaus H; Bergman JJ
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):23-9. PubMed ID: 19602454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
    Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
    JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
    Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus.
    Fitzgerald RC; Saeed IT; Khoo D; Farthing MJ; Burnham WR
    Dig Dis Sci; 2001 Sep; 46(9):1892-8. PubMed ID: 11575441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting.
    Miyashita T; Shah FA; Marti G; Wang J; Armstrong T; Bonde P; Gibson MK; Yoshimura K; Montgomery EA; Duncan MD; Jaffee EM; Harmon JW
    J Gastrointest Surg; 2008 Jan; 12(1):2-7; discussion 7-9. PubMed ID: 17957441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.